Guyana
Tuberculosis profile
| High HIV burden |
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.12 (0.099–0.14) 15 (12–17)
Mortality (HIV+TB only) 0.025 (0.022–0.032) 3.1 (2.8–4.1)
Prevalence  (includes HIV+TB) 1 (0.43–1.9) 131 (54–242)
Incidence  (includes HIV+TB) 0.87 (0.71–1) 109 (90–130)
Incidence (HIV+TB only) 0.2 (0.16–0.23) 25 (20–29)
Case detection, all forms (%) 86 (72–100)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 309 (43) Relapse 23 (9)
Smear-negative 254 (35) Treatment after failure 9 (4)
Smear-unknown / not done 85 (12) Treatment after default 60 (25)
Extrapulmonary 77 (11) Other 152 (62)
Other 0 (0)      
Total new 725   Total retreatment 244  
           
Other (history unknown) 0        
Total new and relapse 748   Total cases notified 969  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 3.3 1.4 1.8
Age < 15 9 15 2
Laboratories 2012
Smear (per 100 000 population) 2.5
Culture (per 5 million population) 6.3
Drug susceptibility testing (per 5 million population) 6.3
Is second-line drug susceptibility testing available? Yes, in and outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 72   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 58  
Retreatment 49  
TB/HIV 2012 Number (%)
TB patients with known HIV status 914 (94)
HIV-positive TB patients 284 (31)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 203 (71)
HIV-positive TB patients on antiretroviral therapy (ART) 168 (59)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 154  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.4–3.1) 14 (4.6–23)
MDR-TB cases among notified pulmonary
TB cases
14 (9–20) 33 (11–56)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 3 (<1%) 1 (<1%) 9
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     9
Financing TB control 2013
National TB programme budget (US$ millions) 1.5
% Funded domestically 38%
% Funded internationally 55%
% Unfunded 8%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data